Coronavirus vaccine

What is this patent about?

{'paragraph': '’686 is related to the field of nucleic acid vaccines, specifically those designed to prevent or treat coronavirus infections, particularly SARS-CoV-2 (the virus that causes COVID-19). The background acknowledges the urgent need for effective vaccines and treatments given the global pandemic and the limitations of existing approaches, such as protein-based vaccines, in terms of cost, production speed, and temperature stability. Nucleic acid-based vaccines offer a promising alternative due to their rapid development and scalable production.'}

{'paragraph': 'The underlying idea behind ’686 is to use a purified messenger RNA (mRNA) molecule to deliver the genetic instructions for a modified SARS-CoV-2 spike protein directly into cells. This mRNA is designed to be translated into a stable, pre-fusion version of the spike protein, which is a key target for neutralizing antibodies. By presenting the immune system with this specific form of the spike protein, the vaccine aims to elicit a strong and protective immune response against the virus.'}

{'paragraph': "The claims of ’686 focus on a specific mRNA construct comprising several key elements. It includes a 5' cap structure for efficient translation, a heterologous 5' untranslated region (UTR) and a heterologous 3' UTR to enhance stability and expression, and a coding sequence for a stabilized SARS-CoV-2 spike protein (S_stab) with specific mutations (K986P, V987P, and D614G). The mRNA may also contain nucleotide substitutions at one or more uracil positions, such as 1-methylpseudouridine or pseudouridine."}

{'paragraph': 'In practice, the mRNA is delivered to cells within the body, where it directs the synthesis of the modified spike protein. The pre-fusion stabilization is achieved through the K986P and V987P mutations, which lock the spike protein in a conformation that is more effective at eliciting neutralizing antibodies. The D614G substitution is included because it is a prevalent mutation in circulating SARS-CoV-2 strains. The heterologous UTRs are included to improve the stability and translation efficiency of the mRNA.'}

{'paragraph': "This approach differs from traditional vaccines that use inactivated viruses or protein subunits. By delivering the genetic instructions directly, the body's own cells become the antigen factories, potentially leading to a more robust and durable immune response. The use of lipid nanoparticles (LNPs) to encapsulate the mRNA further enhances its delivery and protects it from degradation before it can reach the target cells."}